CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 427 enrolled
Drug / intervention
Fluticasone propionate/salmeterol (FS) +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04677959
NCT04677959Phase 4Completed

CONNected Electronic Inhalers Asthma Control Trial 2 ("CONNECT 2"), a 24-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study of Standard of Care Treatment Versus the eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma

Teva Branded Pharmaceutical Products R&D, Inc.·interventional·Posted Dec 21, 2020·Updated Mar 14, 2023

In Brief

A Phase 4 clinical trial evaluating Fluticasone propionate/salmeterol (FS), Albuterol, and 2 other interventions for Asthma. Completed, enrolled 427 participants across 46 sites.

Detailed Summary

The primary objective of this study is to demonstrate the effectiveness of the Digital System (DS) in improving asthma control compared to the Standard of Care (SoC) group. The secondary objective is to describe the asthma management actions by investigational center health care providers (iHCPs) for all participants in both groups, to evaluate short-acting beta2 agonist (SABA) usage and the number of SABA-free days in the DS group, to evaluate adherence patterns to maintenance treatment (FS eMDPI) in the DS group, to assess behavioral correlates of responsiveness to digital health technology among participants for all participants in both groups, to evaluate work productivity and activity impairment in asthma participants in both groups, to assess the usability and acceptability of the DS by participants in the DS group and the investigational center personnel, and to evaluate the safety of FS eMDPI and Albuterol eMDPI.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
202120222023202420252026
First PostedDec 21, 2020
Enrollment StartFeb 16, 2021
Primary CompletionMar 4, 2022
Study CompletionMar 10, 2022
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 5.5 years ago

Interventions

Fluticasone propionate/salmeterol (FS)drug

FS administered via electronic multidose dry powder inhaler (eMDPI) Digital System (DS) with component devices including smart device application (App), Digital Health Platform (DHP), and provider-facing dashboard

Albuteroldrug

Albuterol administered via electronic multidose dry powder inhaler (eMDPI) Digital System (DS) with component devices including smart device application (App), Digital Health Platform (DHP), and provider-facing dashboard

Standard of Care Asthma Medicationdrug

Current inhaled corticosteroid(ICS)/Long-acting beta agonist(LABA) and any additional controller medication for asthma

Standard of Care Rescue Medicationdrug

Current rescue medication